Shingles vaccine deemed effective in people with autoimmune disease.
The herpes zoster vaccine reduces the risk of shingles in older adults with autoimmune disease, even if they are taking immunosuppressants for their condition, but the protection begins to
Vaccinated individuals had a reduced relative risk for shingles of 0.74-0.77, wane after about 5 years, a recent retrospective study found.
"There has been some concern that patients with autoimmune conditions might have a lower immunogenic response to herpes zoster vaccination, especially when treated with immunosuppressive medications such as glucocorticoids," wrote Huifeng Yun, PhD, of the University of Alabama at Birmingham, and her colleagues.
"Reassuringly, we found that in older patients with autoimmune diseases, the herpes zoster vaccine was effective in the short term, and that its effectiveness waned over time," they reported in the Journal of Rheumatology (2017 Mar 15. doi: 10.3899/ jrheum.160685).
The researchers used 2006-2013 Medicare data to calculate the risk of shingles among Medicare recipients who had an autoimmune disease and either did or did not receive the herpes zoster vaccine. All the patients had been enrolled in Medicare for at least 12 continuous months and had a diagnosis of ankylosing spondylitis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or rheumatoid arthritis.
The researchers matched 59,627 patients who received the herpes zoster vaccine with 119,254 unvaccinated patients, based on age, sex, race, calendar year, autoimmune disease type, and use of autoimmune drugs (biologies, disease-modifying antirheumatic drugs, and glucocorticoids). During a follow-up of up to 7 years, the researchers additionally accounted for comorbid medical conditions and concurrent medications each year.
The cohort, with an average age of 73.5 years in both groups, included 53.1% of adults with rheumatoid arthritis, 31.6% with psoriasis, 20.9% with inflammatory bowel disease, 4.7% with psoriatic arthritis, and 1.4% with ankylosing spondylitis.
Those who received the vaccine s had a rate of 0.75 herpes zoster cases per 100 people during the first year, fj which rose to 1.25 cases per 100 people per year at the seventh year after s vaccination. The rate among unvaccinated individuals stayed steady at approximately 1.3-1.7 cases per 100 people per year throughout the study period. These rates, as expected, were approximately 50% higher than in the general population over age 70 without autoimmune disease.
Compared with unvaccinated individuals, vaccinated individuals had a reduced relative risk for shingles of 0.74-0.77 after adjustment for confounders, but the risk reduction remained statistically significant for only the first 5 years after vaccination.
The waning seen with the vaccine's effectiveness "raises the possibility that patients might benefit from a booster vaccine at some point after initial vaccination, although no recommendation currently exists that would support such a practice," the authors wrote.
Dr. Yun has received research funding from Amgen. Other authors disclosed ties to Amgen, AstraZeneca, Bristol-Myers Squibb, Crescendo Bioscience, Janssen, and Pfizer. One author has received research support and consulting fees from Corrona. The study did not note an external source of funding.
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Date:||Apr 15, 2017|
|Previous Article:||MOC option: ABIM offers 2-year, open-book exams.|
|Next Article:||Internal medicine slots increase in March day 2017.|